Table 4 Comparison of the characteristics of the patients receiving tocilizumab who survived versus those who did not
Variable | Survived (n = 72) | Died (n = 79) | P value |
|---|---|---|---|
Age | 52 (42–59) | 55 (46–60) | 0.105 |
Male sex | 48 (66.7) | 59 (74.7) | 0.279 |
Hypertension | 19 (26.4) | 21 (26.6) | 0.979 |
Diabetes | 33 (45.8) | 45 (57) | 0.172 |
Obesity | 3 (4.2) | 11 (13.9) | 0.039 |
Other comorbidities | 2 (2.8) | 3 (3.8) | 0.727 |
Number of comorbidities | 1 (0–1) | 1 (0–2) | 0.082 |
Category | Â | Â | 0.143 |
 E | 63 (87.5) | 62 (78.5) |  |
 F | 9 (12.5) | 17 (21.5) |  |
Oxygen saturation | 88 (85–93) | 85 (79–90) | 0.014 |
CRP | 97.5 (63.5–159) | 90 (56–136) | 0.264 |
Respiratory rate | 30 (30–36) | 36 (30–40) | 0.002 |
Serum Creatinine | 1 (1–1) | 1 (1–2) | 0.001 |
SGOT | 49 (37–75) | 57 (42–72) | 0.169 |
SGPT | 40 (30–58) | 44 (28–68) | 0.977 |
LDH | 701 (515–988) | 608 (462–753) | 1.000 |
Ferritin | 437 (293–947) | 978 (369–2000) | 0.364 |
D-dimer | 1000 (1000–1927) | 1411 (1000–5000) | 0.079 |
IL-6 | 455 (75–984) | Not available |  |
WBC counts (×109/L) | 8.9 (5.85–13.6) | 8.4 (6.1–12.0) | 0.799 |
Neutrophil percentage | 72 (65–78) | 72 (70–75) | 1.000 |
Lymphocyte percentage | 25 (17–29) | 23 (10–27) | 0.469 |
Platelet count (×109/L) | 200 (200–300) | 200 (200–300) | 0.314 |
Day of tocilizumab | 3 (2–6) | 3 (2–5) | 0.865 |
Non-invasive ventilation | 22 (30.6) | 34 (43) | 0.113 |
Invasive ventilation | 1 (1.4) | 21 (26.6) | 0.001 |